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Abstract
Infections caused by methicillin-resistant Staphylococcus aureus (MRSA) incur signiﬁcant costs. We aimed to examine the cost and cost–
beneﬁt of infection control interventions against MRSA and to examine factors affecting economic estimates. We performed a systematic
review of studies assessing infection control interventions aimed at preventing spread of MRSA in hospitals and reporting intervention costs,
savings, cost–beneﬁt or cost-effectiveness. We searched PubMed and references of included studies with no language restrictions up to
January 2012. We used the Quality of Health Economic Studies tool to assess study quality. We report cost and savings per month in 2011
US$. We calculated the median save/cost ratio and the save–cost difference with interquartile range (IQR) range. We examined the effects
of MRSA endemicity, intervention duration and hospital size on results. Thirty-six studies published between 1987 and 2011 fulﬁlled
inclusion criteria. Fifteen of the 18 studies reporting both costs and savings reported a save/cost ratio >1. The median save/cost ratio across
all 18 studies was 7.16 (IQR 1.37–16). The median cost across all studies reporting intervention costs (n = 31) was 8648 (IQR 2025–
19 170) US$ per month; median savings were 38 751 (IQR 14 206–75 842) US$ per month (23 studies). Higher save/cost ratios were
observed in the intermediate to high endemicity setting compared with the low endemicity setting, in hospitals with <500-beds and with
interventions of >6 months. Infection control intervention to reduce spread of MRSA in acute-care hospitals showed a favourable cost/
beneﬁt ratio. This was true also for high MRSA endemicity settings. Unresolved economic issues include rapid screening using molecular
techniques and universal versus targeted screening.
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Background
Infections caused by methicillin-resistant Staphylococcus aureus
(MRSA) incur signiﬁcant morbidity, mortality and costs [1–3].
The adjusted odds ratio for death following MRSA bacteraemia
compared with methicillin-sensitive S. aureus (MSSA) bacter-
aemia was estimated at 1.88 (95% CI 1.33–2.69) [4]. In the
Netherlands, the additional length of stay for a patient with
MRSA bacteraemia compared with MSSA bacteraemia was
estimated at 10 days, with additional costs of €6372 (2011 US
$9688) per patient [5]. An attributable in-hospital cost of
€380 million was estimated for MRSA infections in EU
healthcare systems [6]. In a review of the economic conse-
quences of MRSA, the average cost of an MRSA-infected
patient in Canada was estimated at US$12 216, with hospital-
ization being the major cost driver (81%), followed by barrier
precautions (13%), antimicrobial therapy and laboratory
investigations [7].
Intensive efforts to decrease MRSA infections in some
European countries have resulted in signiﬁcant reductions in
MRSA incidence [8]. According to the European Antimicrobial
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Resistance Surveillance System annual report in 2012, 22.8%%
of all S. aureus bacteraemias reported in 2012 were methicil-
lin-resistant, a signiﬁcant decrease from 41.9% reported in
2006. In the UK, there was a 56% reduction in the number of
reported MRSA bacteraemias between 2004 and 2008 [9].
Such intensive efforts are costly and the cost-effectiveness
of these efforts at the hospital or national level has not been
deﬁned [10]. The main infection control interventions used
against MRSA include screening, contact isolation, cohorting
and decolonization in addition to standard precautions.
Contact isolation requires personal protective equipment;
screening programmes incur laboratory costs (especially if
rapid molecular techniques are used), consumables costs,
clinical staff costs and decolonization costs; patient cohorting
requires dedicated nursing staff. Costs more complicated to
account for include those related to initial building and
construction, restriction of number of beds in an intensive
care unit, closure of a unit, closure of an operating room or
cancellation of an operation.
We performed a systematic review of primary studies
reporting on the cost-effectiveness, cost–beneﬁt or costs
alone of infection control interventions aimed at preventing
spread of MRSA. We aimed to provide an overview of
empirical studies, to obtain a cost–beneﬁt estimate and to
examine factors affecting economic estimates.
Methods
We included studies assessing infection control interventions
aimed at preventing spread of MRSA in hospitals. Interventions
included implementation of surveillance for MRSA, screening
with or without decolonization, contact isolation, droplet
isolation, environmental control and antibiotic stewardship.
Studies were included if they reported at least one of the
following economic analyses: costs of the intervention (inter-
vention cost), costs related to beneﬁt/gain following the
intervention (savings), cost–beneﬁt or cost-effectiveness. Any
unit of effectiveness could be assessed in cost-effectiveness
analyses, including life-years, quality-adjusted life years or
infections prevented. We included studies in which cost
assessment was based on primary study data; we excluded
decision analytic models where the input to the model was
based solely on literature review. We excluded studies
evaluating costs of laboratory tests or equipment only and
studies assessing only beneﬁt by considering a single class of
antibiotics.
We searched PubMed until January 2012 using a structured
search clause (Appendix 1) and the reference lists of all
included articles. We imposed no date or language restric-
tions. Conference proceedings were not sought because we
expected that the level of information provided in an abstract
would be insufﬁcient. Two reviewers independently applied
inclusion criteria and extracted the data from included studies.
Differences in the data extracted were resolved by discussion
with a third review author. Justiﬁcation for excluding studies
from the review was documented.
We primarily aimed to extract the costs of the intervention
and the economic gain following the intervention. When
economic consequences of the intervention were reported at
several time points, we extracted all time points and used the
longest follow up in the primary analysis. When sensitivity
analyses were performed, we extracted base-case ﬁgures. We
extracted not only the total sum of costs and savings, but also
the individual components including personnel (separating
nurse, physician and laboratory technician time), materials,
antimicrobials, laboratory costs, building and refurbishment.
We attempted to extract data on indirect costs, including
intangible and productivity losses qualitatively. In addition, we
extracted data on the components of the infection control
intervention, baseline MRSA endemicity and the effects of the
intervention on clinical infections and colonization with MRSA.
We based MRSA endemicity rates on the percentage of
methicillin-resistant isolates out of all S. aureus clinical isolates
(usually bacteraemia): <1% low, 1–10% moderate and >10%
high [11].
We used the Quality of Health Economic Studies (QHES)
tool, adapted for our review, to assess the studies’ quality
(Appendix 2). The original QHES instrument contains 16
criteria, each with a weighted point value and the maximal
score is 100 [12]. As we assessed primary studies rather than
economic models, some of the QHES criteria were not
relevant. Hence, in the adapted tool, the maximal score was 86
for studies providing cost–beneﬁt or cost-effectiveness anal-
yses and 50 for studies reporting on costs alone. We examined
the effect of the revised QHES score on results through
subgroup analysis.
We expressed costs per month considering the interven-
tion duration for intervention costs and the duration of
follow-up for the save costs. We calculated the save/cost ratio
(values >1 indicating savings larger than costs) and the save–
cost difference (positive values indicating net saving), adjusted
to 2011 US$. All costs reported are in 2011 US$ per month.
Since cost values were not normally distributed, highly
heterogeneous and reported without a dispersion measure,
no formal meta-analysis was performed. We calculated
summary median cost, save, ratio and difference values with
range (minimum–maximum) or interquartile range (IQR) (25–
75% centile). When a range of cost values was reported, we
used the median of the range for the summary estimate. We
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hypothesized a priori that heterogeneity will stem from the
types of interventions, hospital size, population screened and
prevalence of MRSA carriage.
Results
Potentially eligible articles were selected for full-text inspec-
tion, of which 36 studies fulﬁlled the inclusion criteria (Fig. 1).
The studies were published between 1987 and 2011 and all but
one were conducted in acute care hospitals (Table 1). Eighteen
included both the intervention cost and save estimates [13–30]
and 18 studies reported only on the cost [5,31–43] or save
[44–47] estimate. All studies examined the costs associated
with implementation of a new or existing infection control
intervention, whereas one recent study assessed the costs and
harms associated with discontinuation of contact precautions
for MRSA carriers [40]. The studies were most commonly
conducted in hospitals with high MRSA endemicity (17 studies)
and two were performed during an outbreak of MRSA. The
intervention durations ranged between 2 months and
10 years.
The components of the infection control interventions are
detailed in Table 2. A comprehensive ‘search and destroy’
policy [14] was assessed in seven studies, conducted mostly in
low endemicity settings in the Netherlands, Belgium, Germany
and Sweden. It included screening on admission of patients at
risk for MRSA, isolation of patients in single rooms, decolo-
nization and follow-up screening, with variable healthcare
worker screening, suspension from work, visitor screening and
environmental cultures. Of the 33 (92%) studies assessing
patient screening, 20 (55%) also performed decolonization.
Decolonization was more commonly used in studies
conducted in Europe than in the USA, 16/20 (80%) and 3/20
(15%) studies, respectively. Patients were pre-emptively placed
in contact isolation before screening results were available in
12 (36%) of the screening studies. Contact isolation was
included in the intervention in 30 (83%) studies. Few studies
included cohorting of patients or staff (11 and 7 studies,
respectively).
Components of the cost derivation in individual studies are
detailed in Table 3. Common cost components included
personal protective equipment, personnel time, screening
and laboratory materials, and antimicrobials. Costs related to
building or renovation of extra rooms needed for isolation and
cohorting were reported in a single study [16]. The dominant
cost component, when reported, was the loss of bed-days.
Save costs were usually expressed as infections or bed-days
averted using a global sum for the extra costs of an invasive
MRSA infection or per bed-day. A single study considered
potential lives saved as beneﬁt, although no formal cost-effec-
tiveness per life-year was performed (15). Only seven (19%)
studies used discounting for costs or beneﬁts that went
beyond 1 year, ﬁve (14%) performed sensitivity analyses for
the cost or beneﬁt estimates and these were usually limited to
one or few assumptions regarding a single component of the
cost estimate and six (17%) studies reported on an incremen-
tal analysis. The perspective of the economic analysis in all
studies was the hospital, although this was explicitly deﬁned in
only nine (25%). None of the studies quantiﬁed indirect costs.
The median save/cost ratio across all studies reporting both
values (18 studies) was US$7.16 (IQR 1.37–16) and the median
net global saving was US$23 509 (IQR 3194–50 049) per
month. The median cost across all studies reporting interven-
tion costs (31 studies) was US$8648 (IQR 2025–19 170) per
month. The median saving across all studies reporting this (23
studies) was US$38 751 (IQR 14 206–75 842) per month.
Fifteen of the 18 studies reporting both intervention and save
costs (83%) showed that infection control interventions were
economically justiﬁed because the save/cost ratio was >1 or
the save–cost difference was positive (Table 4). Three studies
reported a save/cost ratio <1 and negative save-cost differ-
ence. In two of them PCR was used for universal patient
screening at admission [27] or before surgery [25]. Herr et al.
[30] described that implementation of the German Health
Authority recommendations for prevention and control of
MRSA cost more than the gains of preventing MRSA
transmission. Most (80%) of the costs in this study were
related to lost bed-days in multi-bed rooms where an MRSA
case was isolated.
Effects of the study characteristics on save/cost ratios and
net costs are shown in Table 5. Higher save/cost ratios were
Records identified through 
database searching
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Additional records identified 
through other sources
(n = 17)
Records after duplicates removed
(n = 607)
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FIG. 1. Study ﬂow–studies included in qualitative synthesis.
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observed in an intermediate to high endemicity setting
compared with a low-endemicity setting and were highest
when the intervention was implemented during an outbreak.
Save/cost ratios were higher in smaller hospitals (<500 beds
compared with larger hospitals) and with longer intervention
duration (>6 months compared with shorter duration). The
‘search and destroy’ policy was associated with lower save/
cost ratios than more restricted interventions, as was
pre-emptive isolation before culture results compared with
no isolation before screening results. Screening without
decolonization had higher save/cost ratios than screening with
decolonization. The comparison between targeted and
universal screening was complicated by the fact that targeted
screening was associated with other study characteristics (e.g.
screening using PCR).
The QHES score ranged between 7 and 77 (median 22). We
examined the effect of the total QHES score and one of its
variables (question 9), whether measurement of costs was
appropriate, on results. Studies with QHES score above the
median and appropriate description of cost measurement
showed lower absolute cost and save values and higher save/
cost ratios than studies with poorer methods of reporting.
TABLE 4. Intervention and saving costs
Study ID Study size (n patients if given)
Total intervention
cost per month
(in 2011 US$)
Total saving
cost per month
(in 2011 US$)
Save/cost
ratioa
Save–cost
difference per
month
(in 2011 US$)
Intervention
reported as
efﬁcacious
Wernitz [13] 539 2226 26 969 7.65 24 743 Y
Simoens [14] Hospital-wide, 1900-bed hospital Y
ICU 6393 7454 1.17 1061
Gerontology unit 3717 4327 1.16 610
van Rijen [15] Hospital-wide, 1370-bed hospital 24 539 72 974 1.98 48 435 Y
Vriens [16] Hospital-wide, 1042-bed hospital 29 555 84 444 2.86 54 889 Y
Rao [17] 11 patients and 200 employees 9585 27 437 11.45 17 852 Y
Nixon [18] 1796 elective and 1122 trauma patients 13 825 60 362 4.36 46 537 Y
West [19] 5980 patients in one hospital and
1732 patients in a second hospital
8048 109 169 13.59 101 121 N
Clancy [20] 1890 patients 3927 26 202 6.67 22 275 Y
Knausz [21] Hospital-wide, 1400-bed hospital 32.84 3938 119.89 3905 NS
Karchmer [22] 597 infants 1192–1521 32 024 19.04 30 833–30 504 Y
Gavalda [23] 214 screened patients 1145 11 269 9.84 10 124 NS
Chaix [24] 26-bed medical ICU NA NA 8.46–36.83
per patient
NA Y
Keshtgar [25] 7938 patients in a surgical ward and 1854 in ICU 52 017 47 498 0.91 4519 Y
Jernigan [26] Hospital-wide, 700-bed hospital NA NA NA 2474–56 988 NS
Leonhardt [27] 3255 patients during intervention period
(15 049 overall including before and after phases)
17 254 10 051 0.58 7208 N
Nyman [28]b 8266 patients discharged in 2005 NS
Standard 15 308 34 8703 22.78 333 395
Agar 16 068 348 774 21.71 332 706
PCR 20 801 348 686 16.76 327 885
Bjorholt [29] Hospital-wide, 2628 beds NA NA NA 10380.38 Y
Herr [30] NS 19 697 15 185 0.77 4512 NS
Papia [31] 1742 patients 10 963 NR
Nulens [5] 22 412 patients admitted per year 175 259 NR
Tavolacci [32] 126 patients, 129 admissions 1345 NR
Forward [33] 21 599 patients 5019 NR
Uckay [34]b NS
PCR 176 patients screened, 1942 hospital admissions 8648
Agar 155 patients screened, 1583 hospital admissions 10 537
Wassenberg [35]b NS
Agar 428 patients 1533
Xpert PCR 911 patients 19 729
IDI-GeneOhm PCR 853 patients 11 211
Conterno [36]b
Standard 10 551 patients 89 524
PCR 8528 patients 114 172 N
Could [37] 1421 patients 860 Y
Walsh[38] Hospital-wide, 291 beds, 780 admissions yearly 1090 Y
Morgan [39] 585 patients 2025 NR
Spence [40] 6712 patients 671 N
Garcia [41] 445 infants 1049–1517 NS
Buhlmann [42] 232 patients, 258 episodes 19 170 NR
Creamer [43]
Universal 340 patients 3483 NS
Targetted 552 patients 2213 NS
Bantar [44] 116 945 patient-days 46 423 N
Frank [45] Hospital-wide, 13 943 admissions yearly 45 478 Y
Geissler [46] 1399 patients 42.23–134.01
per patient
Y
Souweine [47] 351 admissions 15.21–23.95
per patient
(antibiotic drug only)
Y
ICU, intensive care unit.
aRatio per month unless otherwise stated.
bIn these studies different laboratory methods for examining screening samples were compared, including standard cultures, agar gel, standard PCR, Xpert or IDI-GeneOhm
commercial real-time PCR essay.
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None of the studies performed a formal cost-effectiveness
analysis to calculate the cost per life-year or per infection
prevented. One study reported a cost of US$37 815 per life
saved (a patient who would have died in-hospital was
discharged alive), for the search and destroy policy in the
Netherlands [15]. The clinical effects of the infection control
interventions were heterogeneously reported as change in
rates of bloodstream infections, other infections and coloni-
zation rates, using various numerators (MRSA or all S. aureus)
and denominators. Qualitatively, the intervention resulted in a
reduction in infection rates in 16 studies and had no effect in
ﬁve studies (Table 4).
Discussion
Most of the published studies show large and signiﬁcant
economic beneﬁt with infection control interventions aimed at
preventing MRSA transmission in acute care hospitals. Overall,
across all studies included in our review, savings were about
seven times higher than costs when an infection control
intervention was applied. The absolute gain was more than US
$20 000 per month for a single hospital. The balance was
even more favourable in intermediate and high MRSA ende-
micity settings. Higher save/cost ratios were reported in
higher quality studies. In the single study considering beneﬁt as
life-years saved, a cost of US$37 815 was calculated for the
search and destroy policy in the Netherlands per in-hospital
death prevented [15]. Considering the extreme scenario of
a median survival of 1.5 years for patients discharged
alive from hospital following an MRSA bacteraemia [48], this
would translate to a cost of US$28 488 per life-year, a ﬁgure
well within the boundaries of acceptable cost-effectiveness
[49–52].
Interventions lasting for more than 6 months were associ-
ated with higher gains than shorter interventions. In the long
run, investments in comprehensive preventive strategies,
including laboratory technologies, construction and trained
personnel, repay. Restricted interventions had higher save/cost
ratios than more intensive interventions. However, we cannot
exclude an association between individual study characteris-
tics, such as restricted interventions reported in long-term
studies. We could not conclude on the cost–beneﬁt of
screening with PCR. Data in our review were insufﬁcient to
compare universal versus targeted screening. In a recent study
in Ireland, targeted screening comprised 62% of admissions
and identiﬁed 92% of colonized patients. Hence, it seems that
in some locations risk factors are able to identify a subgroup of
patients with sufﬁcient speciﬁcity to allow for targeted
screening, so reducing screening costs.
Previous systematic reviews examined the clinical effects of
infection control interventions for MRSA [53–55]. Cooper
et al. [55] included 46 studies published up to 2000. Most of
the studies showed reduction in MRSA transmission. The
strongest level of evidence came from studies reporting on
comprehensive infection control interventions, usually includ-
ing screening, decolonization and isolation or cohorting.
Assessment of the effects of individual interventions and
comparison between types of interventions could not be
performed. The authors highlighted major methodological
weaknesses and inadequate reporting in published research.
Regression to the mean occurring when outbreaks of MRSA
prompted the intervention was also observed in our economic
analysis. Tacconelli et al. [54] focused on screening for MRSA.
Qualitatively, of ten studies performed between 2000 and
2007 and included in the review, four reported a signiﬁcant
decrease in MRSA, one showed a decrease only in some wards
and ﬁve showed no effect. Rapid molecular screening was not
associated with a signiﬁcant reduction in MRSA infection rates
compared with standard culture screening. A review attempt-
ing to summarize both the clinical and economic impact of
infection control measures for MRSA concluded that the
economic analysis could not be performed because of study
heterogeneity [56].
Several limitations of our analysis should be noted. We
restricted our search to fully published articles and could not
formally examine for publication bias. Data are reported in the
primary studies without conﬁdence intervals or other mea-
sures of precision. We did not compute cost-effectiveness
estimates although most studies reported on clinical effective-
ness. Clinical effectiveness ‘units’ were highly variable including
MRSA colonizations, infections, bloodstream or other speciﬁc
infections prevented. We tried to derive cost and cost–beneﬁt
estimates for the individual infection control intervention
components. We could address only two components,
pre-emptive isolation and decolonization. However, even
these subgroup analyses included studies with various combi-
nations of interventions in addition to isolation or decoloni-
zation. A small number of studies reported on an isolated
intervention of antibiotic stewardship and reported only on
intervention costs without examining global savings. All other
intervention components were mixed and heterogeneous. We
did not attempt to estimate the cost-effectiveness of standard
precautions and speciﬁcally hand hygiene alone. However,
these formed the basis of the more complex interventions
addressed in our review.
There are also limitations to the included studies. The
hospital settings in which the intervention was conducted
were not fully described: the general infection control
infrastructure, infection control, clinical microbiology and
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, E582–E593
CMI Farbman et al. Cost–beneﬁt of MRSA control interventions E589
T
A
B
L
E
5
.
E
ff
e
c
t
o
f
st
u
d
y
c
h
a
ra
c
te
ri
st
ic
s
o
n
re
su
lt
sa
In
te
rv
e
n
ti
o
n
c
o
st
p
e
r
m
o
n
th
(i
n
2
0
1
1
U
S
$
)
T
o
ta
l
sa
v
in
g
c
o
st
p
e
r
m
o
n
th
(i
n
2
0
1
1
U
S
$
)
S
a
v
e
/c
o
st
ra
ti
o
a
S
a
v
e
–c
o
st
d
if
fe
re
n
c
e
p
e
r
m
o
n
th
(i
n
2
0
1
1
U
S
$
)
E
n
d
e
m
ic
it
y
L
o
w
4
2
1
5
(6
7
1
–1
7
5
2
5
9
),
n
=
9
,
a
=
1
2
4
9
9
7
2
(1
0
0
5
1
–8
4
4
4
4
),
n
=
4
,
a
=
4
2
.4
2
(0
.5
8
–7
.6
5
),
n
=
4
,
a
=
4
2
4
7
4
3
((
)
7
2
0
3
–5
4
8
8
9
),
n
=
5
,
a
=
5
In
te
rm
e
d
ia
te
/H
ig
h
9
5
8
5
(3
3
–1
1
4
1
7
2
),
n
=
1
8
,
a
=
2
3
4
5
4
7
8
(3
9
3
8
–3
4
8
6
8
6
),
n
=
1
2
,
a
=
1
5
9
.8
4
(0
.7
7
–1
1
9
.8
9
),
n
=
1
0
,
a
=
1
3
2
0
0
6
4
((
)
4
5
1
9
–3
3
3
3
9
5
),
n
=
1
1
,
a
=
1
4
O
u
tb
re
ak
1
2
2
3
(1
0
9
0
–1
3
5
6
(,
n
=
2
,
a
=
2
3
2
0
2
4
,
n
=
1
,
a
=
1
1
9
.0
4
,
n
=
1
,
a
=
1
3
0
8
3
3
–3
0
5
0
4
,
n
=
1
,
a
=
1
St
u
d
y
ye
ar
s
L
as
t
d
ec
ad
e
9
5
9
2
(3
3
–1
1
4
1
7
2
),
n
=
1
6
,
a
=
2
4
3
6
8
5
0
(3
9
3
8
–3
4
8
6
8
6
),
n
=
7
,
a
=
1
0
5
.5
2
(0
.5
8
–1
1
9
.8
9
),
n
=
7
,
a
=
1
0
1
3
0
9
0
(6
1
0
–3
3
3
3
9
5
),
n
=
7
,
a
=
1
0
≤2
0
0
2
8
0
4
8
(8
6
0
–1
7
5
2
5
9
),
n
=
1
3
,
a
=
1
3
3
8
7
5
1
(1
1
2
6
9
–1
0
9
1
6
9
),
n
=
1
0
,
a
=
1
0
8
.7
5
(0
.7
7
–1
9
.0
4
),
n
=
8
,
a
=
8
2
7
2
3
7
((
)
4
5
1
9
–1
0
1
1
2
1
),
n
=
1
0
,
a
=
1
0
H
o
sp
it
al
si
ze
b
>
5
0
0
b
e
d
s
1
9
1
7
0
(3
3
–1
1
4
1
7
2
),
n
=
1
0
,
a
=
1
1
2
6
9
6
9
(3
9
3
8
–1
0
9
1
6
9
),
n
=
6
,
a
=
7
2
.8
6
(1
.1
6
–1
1
9
.8
9
),
n
=
6
,
a
=
7
2
4
7
4
3
(6
1
0
–1
0
1
1
2
1
),
n
=
8
,
a
=
9
≤5
0
0
b
e
d
s
8
8
1
6
(6
7
1
–7
2
5
4
),
n
=
9
,
a
=
1
2
7
7
7
9
6
(1
0
0
5
1
–4
8
6
8
6
),
n
=
6
,
a
=
8
1
5
.1
8
(0
.5
8
–2
2
.7
8
),
n
=
4
,
a
=
6
2
1
4
5
0
3
((
)
7
2
0
3
–3
3
9
5
),
n
=
4
,
a
=
6
In
te
rv
e
n
ti
o
n
d
u
ra
ti
o
n
>
6
m
o
n
th
s
5
0
1
9
(3
3
–1
7
5
2
5
9
),
n
=
1
9
,
a
=
2
3
4
5
9
5
0
(3
9
3
7
–3
4
8
6
8
6
),
n
=
1
2
,
a
=
1
4
8
.7
5
(0
.7
7
–1
1
9
.8
9
),
n
=
1
0
,
a
=
1
2
2
7
2
3
7
((
)
4
5
1
9
–3
3
3
3
9
5
),
n
=
1
2
,
a
=
1
4
≤6
m
o
n
th
s
9
1
1
6
(3
7
1
7
–1
1
4
1
7
2
),
n
=
1
0
,
a
=
1
4
1
8
7
4
4
(4
3
2
6
–1
0
9
1
6
9
),
n
=
5
,
a
=
6
2
.7
6
(0
.5
8
–1
3
.5
9
),
n
=
5
,
a
=
6
9
4
5
6
(6
1
0
–1
0
1
1
2
1
),
n
=
5
,
a
=
6
‘S
e
ar
ch
an
d
d
es
tr
o
y’
Im
p
le
m
en
te
d
1
2
2
1
1
(2
2
2
6
–1
7
5
2
5
9
),
n
=
7
,
a
=
9
2
6
9
6
9
(4
3
2
7
–8
4
4
4
4
),
n
=
4
,
a
=
5
1
.9
8
(1
.1
6
–7
.6
5
),
n
=
4
,
a
=
5
1
7
5
6
1
(6
1
0
–5
4
8
8
9
),
n
=
5
,
a
=
6
N
o
t
im
p
le
m
e
n
te
d
8
3
4
8
(3
3
–1
1
4
1
7
2
),
n
=
2
3
,
a
=
2
8
4
5
4
7
8
(3
9
3
8
–3
4
8
6
8
6
),
n
=
1
3
,
a
=
1
5
1
1
.4
5
(0
.5
8
–1
1
9
.8
9
),
n
=
1
1
,
a
=
1
3
2
6
0
0
3
((
)
7
.2
0
3
–3
3
3
3
9
5
),
n
=
1
2
,
a
=
1
4
P
re
-c
u
lt
u
re
(p
re
-e
m
p
ti
ve
)
is
o
la
ti
o
n
In
cl
u
d
e
d
1
3
8
2
5
(2
2
2
6
–1
7
5
2
5
9
),
n
=
7
,
a
=
7
4
3
6
6
6
(7
4
5
4
–1
0
9
1
6
9
),
n
=
6
,
a
=
6
3
.6
1
(0
.5
8
–1
3
.5
9
),
n
=
6
,
a
=
6
2
4
7
4
3
((
)
7
2
0
3
–1
0
1
1
2
1
),
n
=
7
,
a
=
7
N
o
t
in
cl
u
d
e
d
6
8
3
3
(3
3
–1
1
4
1
7
2
),
n
=
2
3
,
a
=
3
0
3
8
7
5
1
(3
9
3
8
–3
4
8
6
8
6
),
n
=
1
2
,
a
=
1
4
1
0
.6
5
(0
.7
7
–1
1
9
.8
9
),
n
=
1
0
,
a
=
1
2
2
2
2
7
5
((
)
4
5
1
9
–3
3
3
3
9
5
),
n
=
1
1
,
a
=
1
3
Sc
re
e
n
in
g
o
n
ly
ve
rs
u
s
sc
re
e
n
in
g
w
it
h
d
e
co
lo
n
iz
at
io
n
W
it
h
d
ec
o
lo
n
iz
at
io
n
9
5
8
5
(3
3
–1
7
5
2
5
9
),
n
=
1
7
,
a
=
2
1
2
6
9
6
9
(3
9
3
8
–8
4
4
4
4
),
n
=
1
0
,
a
=
1
1
2
.8
6
(0
.7
7
–1
1
9
.8
9
),
n
=
1
0
,
a
=
1
1
1
0
2
5
2
((
)
4
5
1
9
–5
4
8
8
9
),
n
=
1
1
,
a
=
1
2
W
it
h
o
u
t
d
e
co
lo
n
iz
at
io
n
6
5
3
3
(6
7
1
–1
1
4
1
7
2
),
n
=
1
2
,
a
=
1
6
1
0
9
1
6
9
(1
0
0
5
1
–3
4
8
6
8
6
),
n
=
5
,
a
=
7
1
6
.7
6
(0
.5
8
–2
2
.7
8
),
n
=
5
,
a
=
7
6
5
8
9
5
((
)
7
2
0
3
–3
3
3
3
9
5
),
n
=
6
,
a
=
8
Sc
re
e
n
in
g
b
y
u
si
n
g
P
C
R
W
it
h
P
C
R
1
9
1
7
0
(6
7
1
–1
1
4
1
7
2
),
n
=
8
,
a
=
9
4
7
4
9
8
(1
0
0
5
1
–3
4
8
6
8
6
),
n
=
3
,
a
=
3
0
.9
1
(0
.5
8
–1
6
.7
6
),
n
=
3
,
a
=
3
(
)
4
5
1
9
((
)
7
2
0
3
–3
2
7
8
8
5
),
n
=
3
,
a
=
3
O
th
e
r
4
4
7
2
(3
3
–1
7
5
2
5
9
),
n
=
2
5
,
a
=
2
8
2
7
4
3
7
(3
9
3
8
–2
4
8
7
7
4
),
n
=
1
3
,
a
=
1
5
7
.6
5
(0
.9
1
–1
1
9
.8
9
),
n
=
1
3
,
a
=
1
5
2
4
7
4
3
((
)
4
5
1
9
–3
3
3
3
9
5
),
n
=
1
5
,
a
=
1
7
U
n
iv
e
rs
al
ve
rs
u
s
ta
rg
e
te
d
sc
re
e
n
in
g
T
ar
ge
te
d
8
8
1
6
(3
3
–1
7
5
2
5
9
),
n
=
1
6
,
a
=
2
0
1
5
1
8
5
(4
3
2
7
–1
0
9
1
6
9
),
n
=
8
,
a
=
9
7
.6
5
(1
.1
6
–1
1
9
.8
9
),
n
=
8
,
a
=
9
1
0
1
2
4
((
)
4
5
1
2
–1
0
1
1
2
1
),
n
=
8
,
a
=
9
U
n
iv
e
rs
al
8
6
4
7
(8
6
0
–5
2
0
1
7
),
n
=
1
2
,
a
=
1
5
6
0
3
6
2
(1
0
0
5
1
–3
4
8
7
7
4
),
n
=
5
,
a
=
7
6
.7
6
(0
.5
8
–2
2
.7
8
),
n
=
5
,
a
=
7
3
4
4
0
6
((
)
7
2
0
3
–3
3
3
3
9
5
),
n
=
6
,
a
=
8
Q
H
E
S
sc
o
re
(m
e
d
ia
n
=
2
2
)
Q
H
E
S
≥2
2
8
0
4
8
(3
3
–1
1
4
1
7
2
),
n
=
1
5
,
a
=
2
1
3
2
0
2
4
(3
9
3
8
–1
0
9
1
6
9
),
n
=
1
2
,
a
=
1
5
8
.7
5
(0
.9
1
–1
1
9
.8
9
),
n
=
1
1
,
a
=
1
4
2
2
2
7
5
((
)
4
5
1
9
–1
0
1
1
2
1
),
n
=
1
2
,
a
=
1
5
Q
H
E
S
<
2
2
9
1
1
6
(8
6
0
–1
7
5
2
5
9
),
n
=
1
4
,
a
=
1
6
4
6
4
2
3
(1
5
1
8
5
–8
4
4
4
4
),
n
=
5
,
a
=
5
3
.6
1
(0
.7
7
–1
1
.4
5
),
n
=
4
,
a
=
4
2
9
7
3
1
((
)
4
5
1
2
–5
4
8
8
9
),
n
=
5
,
a
=
5
M
e
as
u
re
m
e
n
t
o
f
co
st
s
w
e
re
ap
p
ro
p
ri
at
e
Y
e
s
1
1
0
8
7
(1
0
9
0
–1
7
5
2
5
9
),
n
=
1
9
,
a
=
2
4
3
9
7
6
1
(1
0
0
5
1
–3
4
8
6
8
6
),
n
=
1
0
,
a
=
1
2
1
0
.6
5
(0
.5
8
–2
2
.7
8
),
n
=
1
0
,
a
=
1
2
2
6
0
0
3
((
)
7
2
0
3
–3
3
3
3
9
5
),
n
=
1
2
,
a
=
1
4
N
o
3
7
1
7
1
(3
3
–2
9
5
5
6
),
n
=
1
0
,
a
=
1
3
6
0
3
6
2
(3
9
3
8
–8
4
4
4
4
),
n
=
6
,
a
=
7
3
.6
1
(1
.1
6
–1
1
9
.8
9
),
n
=
5
,
a
=
6
1
4
3
2
4
(6
1
0
–5
4
8
8
9
),
n
=
5
,
a
=
6
IC
U
,
in
te
n
si
ve
ca
re
u
n
it
;
Q
H
E
S,
Q
u
al
it
y
o
f
H
e
al
th
E
co
n
o
m
ic
St
u
d
ie
s
to
o
l.
a
M
e
d
ia
n
(r
an
ge
)
va
lu
e
s
p
re
se
n
te
d
.
St
u
d
ie
s
re
p
o
rt
in
g
o
n
co
st
s
p
e
r
p
at
ie
n
t
w
h
e
re
th
e
n
u
m
b
e
r
o
f
p
at
ie
n
ts
w
as
n
o
t
gi
ve
n
ar
e
n
o
t
in
cl
u
d
e
d
.
n,
n
u
m
b
e
r
o
f
st
u
d
ie
s;
a,
n
u
m
b
e
r
o
f
in
te
rv
e
n
ti
o
n
s.
b
St
u
d
ie
s
in
cl
u
d
e
d
o
n
ly
w
h
e
n
re
p
o
rt
in
g
o
n
n
u
m
b
e
r
o
f
h
o
sp
it
al
b
e
d
s
(o
r
in
fo
rm
at
io
n
av
ai
la
b
le
fo
r
th
e
st
u
d
y
p
e
ri
o
d
).
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, E582–E593
E590 Clinical Microbiology and Infection, Volume 19 Number 12, December 2013 CMI
infectious diseases stafﬁng, microbiology laboratory charac-
teristics, facility or relevant ward design, nurse to patient ratio.
All of these are important to understand the external validity
of the study and all may affect compliance with study policy
(which was stated in eight studies only). However, most or all
studies were conducted in settings with a basic infection
control infrastructure (e.g. existing infection control expertise,
private rooms for contact isolation) and so results are
probably mostly relevant to these settings. As for all
multidrug-resistant bacteria, MRSA is prone to inexplicable
ﬂuctuations in incidence [57]. Existing cost studies did not
perform formal time series analyses to show that the
reductions in MRSA rates were related to the interventions
performed. The cost components considered per intervention
and the derivation of costs were highly variable. Sensitivity
analyses to examine different aspects of the intervention or
beneﬁt were rarely conducted. All studies focused on the
perspective of the hospital, without considering costs and
beneﬁt after patients’ discharge and indirect costs, such as
productivity losses. Formal cost–beneﬁt analyses were rarely
conducted.
In conclusion, infection control interventions reported in
the available literature usually show highly favourable cost–
beneﬁt calculations. This is true also for high MRSA endemicity
settings. Unresolved economic issues include rapid screening
using molecular techniques and universal versus targeted
screening. There is a need for guidance on how to conduct and
report economic analyses of infection control interventions in
primary studies that will allow for comparison between studies
and increase the external validity of individual studies.
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Appendix 1: Search clause
#1: MRSA OR methicillin-resist* OR ‘Methicillin-Resistant Staphylococcus aureus’[Mesh].
#2: Surveillance OR screening OR monitoring OR decolonization.
#3: Contact-isolation OR patient-isolation OR contact-precautions OR cohorting OR single-room OR gown* OR antimicrobial-stewardship OR antibiotic-stewardship OR
(antibiotic AND restriction) OR (antibiotic AND approval) OR antibiotic-guideline* OR (antibiotic AND streamline*) OR
(antibiotic AND cycling).
#4: #2 OR #3.
#5: #1 AND #4.
#6: Cost OR costs OR cost-effectiveness OR cost-beneﬁt OR cost-utility OR cost-minimization OR ‘Economics’[Mesh] OR ‘Economics, Hospital’[Mesh]
OR ‘Costs and Cost Analysis’[Mesh] OR ‘Cost-Beneﬁt Analysis’[Mesh] OR ‘Cost Control’[Mesh] OR ‘Health Care Costs’[Mesh] OR ‘Direct Service Costs’[Mesh] OR ‘Hospital
Costs’[Mesh].
#7: #5 AND #6.
Appendix 2: The Quality of Health Economic Studies (QHES) instrument adapted for our
review
Question Used in adapted QHES a Score
1 Was the study objective presented in a clear, speciﬁc and measurable manner? C,T 7
2 Were the perspective of the analysis (e.g. societal, third-party payer) and reasons for its selection stated? C,T 4
3 Were variable estimates used in the analysis from the best available source (i.e. randomized controlled
trial—best; expert opinion—worst)?
N 8
4 If estimates came from a subgroup analysis, were the groups pre-speciﬁed at the beginning of the study? N 1
5 Was uncertainty handled by: (i) statistical analysis to address random events; (ii) sensitivity analysis to
cover a range of assumptions?
C,T 9
6 Was incremental analysis performed between alternatives for resources and costs? C,T 6
7 Was the methodology for data abstraction (including the value of health states and other beneﬁts) stated? N 5
8 Did the analytic horizon allow time for all relevant and important outcomes? Were beneﬁts and costs that
went beyond 1 year discounted (3–5%) and justiﬁcation given for the discount rate?
C,T 7
9 Was the measurement of costs appropriate and the methodology for the estimation of quantities and unit
costs clearly described?
C,T 8
10 Were the primary outcome measure(s) for the economic evaluation clearly stated, and were the major
short-term, long-term and negative outcomes included?
T 6
11 Were the health-outcome measures/scales valid and reliable? If previously tested valid and reliable
measures were not available, was justiﬁcation given for the measures/scales used?
T 7
12 Were the economic model (including structure), study methods and analysis, and the components of the
numerator and denominator displayed in a clear, transparent manner?
T 8
13 Were the choice of economic model, main assumptions and limitations of the study stated and justiﬁed? T 7
14 Did the author(s) explicitly discuss direction and magnitude of potential biases? C,T 6
15 Were the conclusions/recommendations of the study justiﬁed and based on the study results? T 8
16 Was there a statement disclosing the source of funding for the study? C,T 3
Total 100
aThe QHES instrument contains 16 dichotomous (Yes/No) items, each weighted by its importance as determined by an expert panel of health economists. The maximal score is
100 and the quality score is calculated by subtracting points from 100 for questions answered with No. We omitted several items from our quality assessment, because we
included primary studies rather than cost-effectiveness models. N – not used in our review, C – used for studies describing costs alone, T – used for studies describing
cost-effectiveness or cost–beneﬁt. Hence, the maximal score for studies describing costs alone was 50 and for studies describing cost-effectiveness or cost–beneﬁt was 86.
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